Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.57 |
| ▸ | FLT3 | P36888 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389521 | 0.89 | GPR119 (0.73) | GPR119 | |
| SCHEMBL3866032 | 0.85 | GPR119 (0.48) | GPR119FLT3CDK2CDK6EGFR | |
| SCHEMBL4721017 | 0.84 | GPR119 (0.58) | GPR119FLT3CDK2CDK6CCNA2 | |
| SCHEMBL390039 | 0.83 | GPR119 (0.72) | GPR119 | |
| SCHEMBL5263512 | 0.82 | GPR119 (0.51) | GPR119FLT3CDK2CDK6EGFR | |
| SCHEMBL4719558 | 0.79 | GPR119 (0.57) | GPR119FLT3CDK2CDK6CCNA2 | |
| SCHEMBL2783591 | 0.78 | GPR119 (0.57) | GPR119EGFRKDR | |
| SCHEMBL389816 | 0.78 | GPR119 (0.75) | GPR119 | |
| SCHEMBL1070555 | 0.78 | GPR119 (0.47) | GPR119FLT3CDK2CDK6EGFR | |
| SCHEMBL5048764 | 0.76 | GPR119 (0.49) | GPR119FLT3CDK2CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |